Respiratory Syncytial Virus Infections Cochrane Pediatric Emergency Medicine Reviews
Browse Cochrane Pediatric Emergency Medicine Reviews
Browse Cochrane Pediatric Emergency Medicine Reviews
Cochrane Systematic Review: Heliox inhalation therapy for bronchiolitis in infants
Cochrane Systematic Review: Heliox inhalation therapy for bronchiolitis in infants
- Visit
Liet JM, Ducruet T, Gupta V, Cambonie G.
Liet JM, Ducruet T, Gupta V, Cambonie G.
Objectives: To assess heliox in addition to standard medical care for acute bronchiolitis in infants.
Objectives: To assess heliox in addition to standard medical care for acute bronchiolitis in infants.
Cochrane Systematic Review: Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children
Cochrane Systematic Review: Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children
- Visit
Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.
Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.
Objectives: To assess the effectiveness and safety of palivizumab prophylaxis compared with placebo, or another type of prophylaxis, in reducing the risk of complications (hospitalisation due to RSV infection) in high-risk infants and children. To assess the cost-effectiveness (or cost-utility) of palivizumab prophylaxis compared with no prophylaxis in infants and children in different risk groups.
Objectives: To assess the effectiveness and safety of palivizumab prophylaxis compared with placebo, or another type of prophylaxis, in reducing the risk of complications (hospitalisation due to RSV infection) in high-risk infants and children. To assess the cost-effectiveness (or cost-utility) of palivizumab prophylaxis compared with no prophylaxis in infants and children in different risk groups.
Cochrane Systematic Review: Ribavirin for respiratory syncytial virus infections of the lower respiratory tract in infants and young children
Cochrane Systematic Review: Ribavirin for respiratory syncytial virus infections of the lower respiratory tract in infants and young children
- Visit
Ventre K, Randolph A.
Ventre K, Randolph A.
Objectives: The objective of this review is to assess the efficacy of aerosolized ribavirin for infants and children with lower respiratory tract infections due to RSV.
Objectives: The objective of this review is to assess the efficacy of aerosolized ribavirin for infants and children with lower respiratory tract infections due to RSV.
Cochrane Systematic Review: Antibiotics for persistent cough or wheeze following acute bronchiolitis in children
Cochrane Systematic Review: Antibiotics for persistent cough or wheeze following acute bronchiolitis in children
- Visit
McCallum GB, Morris PS, Chang AB.
McCallum GB, Morris PS, Chang AB.
Objectives: To determine the effectiveness of antibiotics compared to a control (no treatment or placebo) for persistent respiratory symptoms (within six months), following acute bronchiolitis.
Objectives: To determine the effectiveness of antibiotics compared to a control (no treatment or placebo) for persistent respiratory symptoms (within six months), following acute bronchiolitis.
Cochrane Systematic Review: Heliox inhalation therapy for bronchiolitis in infants
Cochrane Systematic Review: Heliox inhalation therapy for bronchiolitis in infants
- Visit
Liet JM, Ducruet T, Gupta V, Cambonie G.
Liet JM, Ducruet T, Gupta V, Cambonie G.
Objectives: To assess heliox in addition to standard medical care for acute bronchiolitis in infants.
Objectives: To assess heliox in addition to standard medical care for acute bronchiolitis in infants.
Cochrane Systematic Review: Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children
Cochrane Systematic Review: Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children
- Visit
Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.
Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.
Objectives: To assess the effectiveness and safety of palivizumab prophylaxis compared with placebo, or another type of prophylaxis, in reducing the risk of complications (hospitalisation due to RSV infection) in high-risk infants and children. To assess the cost-effectiveness (or cost-utility) of palivizumab prophylaxis compared with no prophylaxis in infants and children in different risk groups.
Objectives: To assess the effectiveness and safety of palivizumab prophylaxis compared with placebo, or another type of prophylaxis, in reducing the risk of complications (hospitalisation due to RSV infection) in high-risk infants and children. To assess the cost-effectiveness (or cost-utility) of palivizumab prophylaxis compared with no prophylaxis in infants and children in different risk groups.
Cochrane Systematic Review: Ribavirin for respiratory syncytial virus infections of the lower respiratory tract in infants and young children
Cochrane Systematic Review: Ribavirin for respiratory syncytial virus infections of the lower respiratory tract in infants and young children
- Visit
Ventre K, Randolph A.
Ventre K, Randolph A.
Objectives: The objective of this review is to assess the efficacy of aerosolized ribavirin for infants and children with lower respiratory tract infections due to RSV.
Objectives: The objective of this review is to assess the efficacy of aerosolized ribavirin for infants and children with lower respiratory tract infections due to RSV.
Cochrane Systematic Review: Antibiotics for persistent cough or wheeze following acute bronchiolitis in children
Cochrane Systematic Review: Antibiotics for persistent cough or wheeze following acute bronchiolitis in children
- Visit
McCallum GB, Morris PS, Chang AB.
McCallum GB, Morris PS, Chang AB.
Objectives: To determine the effectiveness of antibiotics compared to a control (no treatment or placebo) for persistent respiratory symptoms (within six months), following acute bronchiolitis.
Objectives: To determine the effectiveness of antibiotics compared to a control (no treatment or placebo) for persistent respiratory symptoms (within six months), following acute bronchiolitis.
